Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $19.40.
TBPH has been the subject of a number of research reports. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, BTIG Research reiterated a “neutral” rating on shares of Theravance Biopharma in a report on Thursday.
Check Out Our Latest Research Report on TBPH
Theravance Biopharma Price Performance
Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last issued its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The company had revenue of $20.73 million during the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, equities analysts anticipate that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.
Insider Buying and Selling at Theravance Biopharma
In related news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the completion of the sale, the senior vice president directly owned 213,476 shares in the company, valued at $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider directly owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 350,011 shares of company stock worth $6,016,830. Insiders own 7.65% of the company’s stock.
Institutional Investors Weigh In On Theravance Biopharma
Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Theravance Biopharma during the first quarter valued at approximately $2,076,000. Wedge Capital Management L L P NC bought a new position in Theravance Biopharma in the second quarter worth approximately $2,190,000. Precision Wealth Strategies LLC bought a new position in Theravance Biopharma in the first quarter worth approximately $1,019,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Theravance Biopharma during the second quarter worth $1,071,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 124,658 shares during the period. Institutional investors own 99.10% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.
Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
